Back to discover
Drug

Tapinarof

In clinical development
ClassAryl hydrocarbon receptor agonistEmerging researchLate-stage development

Also known as Vtama, 3,5-Dihydroxy-4-isopropyl-trans-stilbene.

RxNorm2602286ChEMBLCHEMBL259571ATCD05AX07UNII84HW7D0V04
2
Research papers
4
Active clinical trials
Aryl hydrocarbon receptor
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

An Open-label, Phase II Study to Evaluate the Clinical Efficacy and Safety of Tapinarof for Adult Patients With Palmoplantar Keratoderma

Clinical trial2026-06-23Results expected Q4 2027 · ClinicalTrials.gov

Utilization of a Cutaneous Therapy In Situ Microdevice

Clinical trial2026-06-03Results expected Q2 2030 · ClinicalTrials.gov

Tapinarof for Cutaneous Lupus Erythematosus

Clinical trial2026-04-29Results expected Q4 2027 · ClinicalTrials.gov

A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults

Clinical trial2025-06-12Results posted · ClinicalTrials.gov

A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults

Clinical trial2025-06-12Results posted · ClinicalTrials.gov

Open Label, Observational Study, Evaluating VTAMA® (Tapinarof) Cream, 1% QD in Psoriasis Patients Being Treated With Biologic Agents.

Clinical trial2023-10-18Completed · ClinicalTrials.gov

Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.

Research2021-12-01The New England journal of medicine

Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis.

Research2020-07-29International journal of molecular sciences

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Tapinarof
Aliases & brands
Vtama3,5-Dihydroxy-4-isopropyl-trans-stilbene
RxNorm CUI
2602286
ChEMBL ID
CHEMBL259571
ATC codes
D05AX07
UNII
84HW7D0V04
Primary mechanism
Aryl hydrocarbon receptor agonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Aryl hydrocarbon receptor
AHR · P35869
AGONISTAryl hydrocarbon receptor agonist

Clinical trials

7 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
7
registered trials across all phases
LATEST COMPLETION 2023
4
Active studies
3
Recruiting
5
Late-stage (III+)
3
Completed
PHASE DISTRIBUTIONn = 7
Early Phase 11Phase 21Phase 2 / 31Phase 32Phase 42

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Utilization of a Cutaneous Therapy In Situ Microdevice

Not yet recruitingPH IVUniversity of California, San Franciscon=102030

Open Label, Observational Study, Evaluating VTAMA® (Tapinarof) Cream, 1% QD in Psoriasis Patients Being Treated With Biologic Agents.

CompletedPH IVPsoriasis Treatment Center of Central New Jerseyn=302023

Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)

Enrolling by invitationPH II/IIIWake Forest University Health Sciencesn=402026

A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults

CompletedPH IIIOrganon and Con=5152020

A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults

CompletedPH IIIOrganon and Con=5102020

Recent completions

Trials that read out recently, adding to the completed evidence base.

Open Label, Observational Study, Evaluating VTAMA® (Tapinarof) Cream, 1% QD in Psoriasis Patients Being Treated With Biologic Agents.

CompletedPH IVPsoriasis Treatment Center of Central New Jerseyn=302023

A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults

CompletedPH IIIOrganon and Con=5152020

A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults

CompletedPH IIIOrganon and Con=5102020

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20202021
Most influential

Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis.

International journal of molecular sciences · 2020 · 259 cites

Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.

The New England journal of medicine · 2021 · 141 cites
Recent papers

Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.

The New England journal of medicine · 2021 · 141 cites

Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis.

International journal of molecular sciences · 2020 · 259 cites
Journals, researchers & institutions
Top journals
  • International journal of molecular sciences1
  • The New England journal of medicine1
Leading researchers
  • Armstrong AW1
  • Bagel J1
  • Bissonnette R1
  • Brown PM1
  • Ehst B1
  • Fromowitz J1
  • Furue M1
  • Guenthner S1
Leading institutions
free-text, unnormalised
  • From the Icahn School of Medicine at Mount Sinai1
  • Graduate School of Medical Sciences1
  • Research and Clinical Center for Yusho and Dioxin1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Coal Tar

Studied across the same disease area as Tapinarof in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials